Terns Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Amy Burroughs
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1yr |
| CEO ownership | 0.02% |
| Management average tenure | 1yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Oct 21Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14CEO
Amy Burroughs (54 yo)
1yr
Tenure
Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Treasurer | 4.5yrs | US$3.14m | 0.027% $ 103.4k | |
| CEO & Director | 1yr | no data | 0.022% $ 85.2k | |
| Chief Legal Officer | less than a year | no data | no data | |
| Senior Vice President of Research | 3.1yrs | no data | no data | |
| Chief Medical Officer | 1.8yrs | no data | 0.064% $ 242.0k | |
| Chief Business Officer | less than a year | no data | no data | |
| Chief Development Officer | less than a year | no data | no data | |
| Senior Vice President of Medical Affairs | 1.1yrs | no data | no data | |
| Senior VP of CMC | less than a year | no data | no data | |
| VP of Finance & Controller | 1.1yrs | no data | no data |
1.0yrs
Average Tenure
46.5yo
Average Age
Experienced Management: TERN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1yr | no data | 0.022% $ 85.2k | |
| Independent Director | 6.3yrs | US$298.99k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$304.99k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.8yrs | US$299.99k | 0.56% $ 2.1m | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Chairman | 4.2yrs | US$340.15k | 0% $ 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 2.6yrs | US$303.06k | 0% $ 0 | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 4.2yrs | US$480.49k | 0% $ 0 |
4.2yrs
Average Tenure
53yo
Average Age
Experienced Board: TERN's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 09:16 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |